Objectives An investigator-initiated, double-blinded, placebo-controlled, treat-to-target
protocol (Clinical Trials: NCT00660647) studied whether adalimumab added to …

Novel deazaxanthine-based DPP-4 inhibitors have been identified that are potent (IC50<
10nM) and highly selective versus other dipeptidyl peptidases. Their synthesis and SAR are …

Objectives. To investigate the frequency of anti-infliximab antibodies in patients with RA and
the associations with adverse drug reactions and treatment failure. Methods. Based on the …

At least 30% of patients with rheumatoid arthritis (RA) do not respond to biologic agents,
which emphasizes the need of predictive biomarkers. We aimed to identify microRNAs …

Tributylgermanium hydride (Bu3GeH) can be used as an alternative to tributyltin hydride
(Bu3SnH) as a radical generating reagent with a wide range of radical substrates …

PI3Kδ is a lipid kinase and a member of a larger family of enzymes, PI3K class IA (α, β, δ)
and IB (γ), which catalyze the phosphorylation of PIP2 to PIP3. PI3Kδ is mainly expressed in …

Objective Recently, two genome-wide association studies identified single nucleotide
polymorphisms (SNPs) significantly associated with the treatment response to tumor …

Objective. The aim was to identify plasma (ie, cell-free) microRNA (miRNA) predicting
antitumor necrosis and/or methotrexate (MTX) treatment response in patients enrolled in an …

Objectives To study clinical and radiographic outcomes after withdrawing 1 year's
adalimumab induction therapy for early rheumatoid arthritis (eRA) added to a methotrexate …

Objectives To investigate whether a treat-to-target strategy with methotrexate and intra-
articular glucocorticosteroid injections suppresses MRI inflammation and halts structural …